OncoMatch/Clinical Trials/NCT05098132
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Is NCT05098132 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including STK-012 and pembrolizumab for advanced solid tumor.
Treatment: STK-012 · pembrolizumab · pemetrexed · carboplatin — This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative, non-squamous, non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) negative (tps <1%)
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IV, IIIB, IIIC
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior immune checkpoint inhibitor (anti-PD[L]1 and/or anti-CTLA-4) treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center · Tucson, Arizona
- Beverly Hills Cancer Center · Beverly Hills, California
- Providence Medical Foundation · Fullerton, California
- UC San Diego Moores Cancer Center · La Jolla, California
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05098132 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 negative is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage IV or IIIB or IIIC is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages